Sensitivity of Organoids to predict Treatment Outcome in Breast Cancer

• Research type

  Research Study

• Full title

  SOTO-BC: Prospective study to correlate the treatment Sensitivity of patient-derived Organoids with Treatment Outcomes in breast cancer patients with brain and/or extra-cranial metastases

• IRAS ID

  315973

• Contact name

  Anthony Kong

• Contact email

  anthony.kong@kcl.ac.uk

• Sponsor organisation

  Kings College London

• Duration of Study in the UK

  1 years, 4 months, 30 days

• Research summary

  Breast cancer refers to the erratic growth and proliferation of cells that originate in the breast tissue. Brain metastases occur when cancer spreads from its original location to the brain. This can happen via the blood stream or the lymph system. Breast cancer is a common cause of brain metastases, with metastases occurring in at least 10-16% of patients. Metastasis can occur anywhere in the body but we are mainly interested in brain metastasis for this study, but we will also include patients with other types.
  The aim of this study is to see whether metastatic tumours that are removed from patients undergoing surgery can be grown in a laboratory. Cancer cells can be grown in a laboratory to form tumour-like 3-D structures mimicking how tumours look inside a patient. These structures are called organoids or patient-derived organoids (PDOs). This study aims to address the hypothesis that 1) it would be possible to generate patient-derived organoids from metastases of the brain or from other areas of the body; 2) that treatment of the organoids with standard cancer treatments, like radiation or chemotherapy, can give information about how sensitive the tumour cells are to these treatments; and 3) that it would be possible to see whether the outcome of the patient's cancer treatment can match how the organoid responds to the same treatment in the laboratory. If this study shows that this organoid technique is possible, we would then like to evaluate the growth of breast cancer with metastases into a larger study. Eventually, we hope that by using organoids, we can better predict how a patient will respond to cancer treatment and tailor each treatment specifically for the patient.

• REC name

  North East - Tyne & Wear South Research Ethics Committee

• REC reference

  24/NE/0022

• Date of REC Opinion

  11 Jan 2024

• REC opinion

  Favourable Opinion